Company intelligence / Profile preview

EG Labo

Boulogne-Billancourt, Ile-de-France, Franceeglabo.fr ↗

Ownership: Private
Employees: ~120
Development stage: Other

Overview

EG Labo has over 820 marketed products covering most major therapeutic classes. The company sells approximately 40 million units per year in France. It offers reimbursable generics to reduce costs for patients while maintaining quality standards. The portfolio also includes non-reimbursable specialties and well-known OTC brands such as Synthol® and Duofilm®. In recent years the company has expanded into strategic segments like smoking cessation.

Therapeutic areas: Other
Modalities: Small moleculeBiologic (for biosimilars)Over-the-counter product
Industry: Biotech

Partnerships

Not specifically disclosed; strong relationships with pharmacists/hospitals in France due to generic/OTC business model

Beyond the preview

Go deeper on EG Labo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG Labo.